Quick Answer
Aquestive Therapeutics, Inc. reported Total Assets of $160.43 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed an increase of +58.2% in Total Assets from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $39.84 million | Q3 2018: $90.01 million | Q1 2019: $67.98 million | Q2 2019: $50.41 million | Q3 2019: $48.82 million | Q1 2020: $64.49 million | Q2 2020: $63.55 million | Q3 2020: $50.42 million | Q1 2021: $61.92 million | Q2 2021: $66.88 million | Q3 2021: $65.29 million | Q1 2022: $56.53 million | Q2 2022: $56.31 million | Q3 2022: $51.85 million | Q1 2023: $61.29 million | Q2 2023: $56.99 million | Q3 2023: $59.45 million | Q1 2024: $129.52 million | Q2 2024: $117.61 million | Q3 2024: $109.96 million | Q1 2025: $102.23 million | Q2 2025: $93.70 million | Q3 2025: $163.56 million.
- Over the full 9 years of available data (2017 to 2025), Aquestive Therapeutics, Inc.'s Total Assets has grown by 272.1%.
- Historical annual values: Fiscal year 2025: $160.43 million | Fiscal year 2024: $101.42 million | Fiscal year 2023: $57.42 million | Fiscal year 2022: $57.07 million | Fiscal year 2021: $61.99 million | Fiscal year 2020: $62.88 million | Fiscal year 2019: $78.48 million | Fiscal year 2018: $86.85 million | Fiscal year 2017: $43.12 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: